STING1 and neoplasm: Given the high prevalence of defects inDNA damage repair pathways, in 50% of HGSC tumours, future studies should evaluatethe efficacy of STING agonist as a combinatorial immunotherapeutic agent in tumourswith defects in DNA damage such that excessive IFN activation and a state oftolerance is avoided.